Literature DB >> 22076586

Enhancement of cytotoxic and pro-apoptotic effects of 2-aminophenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell line RLN-10 in combination with 2-deoxy-D-glucose.

Akira Takemura1, Xiao-Fang Che, Takafumi Tabuchi, Shota Moriya, Keisuke Miyazawa, Akio Tomoda.   

Abstract

The cytotoxic and pro-apoptotic effects of a single dose of 2-aminophenoxazine-3-one (Phx-3) or 2-deoxyglucose (2-DG) or of a combined dose of Phx-3 and 2-DG were studied in the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2 and the rat normal hepatocellular cell line RLN-10. The number of viable cells decreased in a dose-dependent manner, when dRLh-84, HepG2 or RLN-10 cells were treated with 2-DG (0.5-20 mM) or Phx-3 (1-50 µM) alone at 37˚C for 48 h. When these cells were treated with 10 mM 2-DG and different concentrations of Phx-3, the number of viable cells decreased dose-dependently and in an additive manner for these agents. A single dose of 2 or 10 µM Phx-3 induced apoptotic morphology characterized by nuclear condensation and cell shrinkage in dRLh-84, HepG2 and RLN-10 cells, while a single dose of 10 mM 2-DG did not. When Phx-3 (2 or 10 µM) treatment was combined with 2-DG (10 mM) treatment in these three cell lines, the cells with apoptotic morphology increased extensively, which was confirmed by flow cytometric analysis. In addition, autophagic morphology characterized by cytosolic vacuole formation was significantly increased in the hepatocellular carcinoma cell lines dRLh-84 and HepG2 but not in the normal hepatocellular cell line RLN-10 after a single dose of Phx-3 or 2-DG or a combined dose of Phx-3 and 2-DG. Furthermore, when dRLh-84 and HepG2 cells were treated with Phx-3 alone or a combined dose of Phx-3 and 2-DG, depolarization of the mitochondria was extensive, but that of the normal cell line RLN-10 was not. These results may imply that the mechanism for the apoptosis of hepatocellular carcinoma cells caused by Phx-3 alone or a combined dose of Phx-3 and 2-DG differs from that of the normal cell line RLN-10. The present results demonstrate that Phx-3 alone may be beneficial for targeting liver cancer and that its anticancer activity may be enhanced by 2-DG. However, a combined dose of Phx-3 and 2-DG may exert adverse effects on normal liver cells, as evidenced by the cytotoxic and pro-apoptotic effects of the combined treatment in the rat normal hepatocellular cell line RLN-10.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22076586     DOI: 10.3892/or.2011.1531

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?

Authors:  Lynn Jeanette Savic; Julius Chapiro; Gregor Duwe; Jean-François Geschwind
Journal:  Hepat Oncol       Date:  2016-01-01

2.  2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2016-12-16       Impact factor: 2.967

3.  Cytotoxicity effect of degraded and undegraded kappa and iota carrageenan in human intestine and liver cell lines.

Authors:  Shahrul Hisham Zainal Ariffin; Wong Woan Yeen; Intan Zarina Zainol Abidin; Rohaya Megat Abdul Wahab; Zaidah Zainal Ariffin; Sahidan Senafi
Journal:  BMC Complement Altern Med       Date:  2014-12-17       Impact factor: 3.659

Review 4.  Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.

Authors:  Jiao Feng; Jingjing Li; Liwei Wu; Qiang Yu; Jie Ji; Jianye Wu; Weiqi Dai; Chuanyong Guo
Journal:  J Exp Clin Cancer Res       Date:  2020-07-06

Review 5.  Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies.

Authors:  Yi Zhang; Qiong Li; Zhao Huang; Bowen Li; Edouard C Nice; Canhua Huang; Liuya Wei; Bingwen Zou
Journal:  Cancers (Basel)       Date:  2022-09-21       Impact factor: 6.575

Review 6.  Pharmacological Activities of Aminophenoxazinones.

Authors:  Jesús G Zorrilla; Carlos Rial; Daniel Cabrera; José M G Molinillo; Rosa M Varela; Francisco A Macías
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

7.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.